Quantcast

Latest HspE7 Stories

2008-09-25 09:00:54

Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP) today announced completion of its U.S. Food and Drug Administration (FDA) pivotal clinical trial for its LightTouch(TM) non-invasive cervical cancer detection device. The GT LightTouch technology systematically and rapidly scans the cervix to identify cancers and pre-cancers painlessly and non-invasively by analyzing the wavelengths of light reflected from cervical tissue. Since the pivotal trial began, approximately 1,900 women have...

2008-09-15 09:00:58

The FDA has approved Merck & Co's Gardasil vaccine for the prevention of vaginal and vulvar cancer caused by human papillomavirus types 16 and 18 in girls and women ages nine to 26. Regarding the prevention of vulvar and vaginal cancer, Gardasil's manufacturer, Merck & Co followed more than 15,000 participants from the original studies for about two additional years. Approximately half had received Gardasil as part of the original study - the other half did not receive Gardasil and...

2008-08-12 09:01:37

SAN DIEGO, Aug. 12 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the second quarter and six months ended June 30, 2008, and highlighted several recent product developments and corporate milestones. (Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO) Recent product and corporate highlights: -- Key clinical results from our Phase 1 trial of HspE7, a therapeutic treatment for patients with cervical...

2008-07-28 09:01:47

SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that it has completed analysis of immunological data from all four cohorts of its Phase 1 clinical trial for HspE7, its lead product candidate. HspE7 is a therapeutic treatment for patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer. The primary cause of CIN is infection with certain human papillomavirus (HPV) types, of which HPV16 is the most...

834d3ce0350bfc1014c3a7a8c731293e1
2008-04-25 09:49:48

Papers presented at the 1st European Lung Cancer Conference, jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland highlight emerging evidence that common viruses may contribute to the development of lung cancer.Experts agree that smoking is by far the most important factor that contributes to lung cancer development. But other factors can play a role in some cases.In one report at...

2006-09-04 02:00:00

LONDON (Reuters) - GlaxoSmithKline's experimental vaccine against a virus that causes cervical cancer could cut the number of cases and deaths from the illness by up to 76 percent, the drug company said on Monday. The vaccine known as Cervarix prevents infection from two strains of the human papillomavirus (HPV) which account for about 70 percent of cases of cervical cancer. In a computer model study sponsored by GlaxoSmithKline and presented at a medical conference in Prague, the researchers...

2006-09-04 02:00:00

LONDON -- GlaxoSmithKline's experimental vaccine against a virus that causes cervical cancer could cut the number of cases and deaths from the illness by up to 76 percent, the drug company said on Monday. The vaccine known as Cervarix prevents infection from two strains of the human papillomavirus (HPV) which account for about 70 percent of cases of cervical cancer. In a computer model study sponsored by GlaxoSmithKline and presented at a medical conference in Prague, the researchers...

2006-04-06 00:45:00

LONDON -- A vaccine that protects women against a virus that causes cervical cancer is effective for more than four years, researchers said on Thursday. They found that women given GlaxoSmithKline Plc's cervical cancer vaccine Cervarix had high levels of antibodies against two of types of the human papillomavirus (HPV) for up to 4.5 years after receiving their last dose. "These findings set the stage for widescale adoption of HPV vaccination for prevention of cervical cancer," said Dr Diane...

2006-04-05 14:30:00

LONDON -- A vaccine that protects women against a virus that causes cervical cancer is effective for more than four years, researchers said on Thursday. They found that women given GlaxoSmithKline Plc's cervical cancer vaccine Cervarix had high levels of antibodies against two of types of the human papillomavirus (HPV) for up to 4.5 years after receiving their last dose. "These findings set the stage for widescale adoption of HPV vaccination for prevention of cervical cancer," said Dr Diane...

2005-12-26 09:24:32

NEW YORK (Reuters Health) - Women with certain types of human papilloma virus (HPV) infection run the risk of developing CIN -- cervical intraepithelial neoplasia, a type of pre-cancer. However, contrary to previous concerns, their risk is not affected if they use hormonal contraceptives, or by their history of pregnancy and childbearing, researchers have found. Previous studies have suggested an increased risk of CIN with long-term oral contraceptive use and having more than one...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'